Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
Open Access
- 20 December 2017
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2017, 1-14
Abstract
The chimeric antigen receptor-modified immune effector cell (CAR-T and CAR-NK) therapies are newly developed adoptive treatments of cancers. However, their therapeutic efficacy against solid tumors is limited. Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a promising strategy. We developed an epidermal growth factor- (EGFR-) specific third-generation CAR. NK-92 cells were modified with the CAR by lentivirus infection. The specific killing ability of the CAR-modified NK-92 cells (CAR-NK-92) against renal cell carcinoma (RCC) cell lines was confirmed in vitro. The synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells were investigated in vitro and in vivo. Our results showed that the CAR-NK-92 cells lyse RCC cells in an EGFR-specific manner. Treatment with cabozantinib could increase EGFR and decrease PD-L1 membrane surface expression in RCC cells and enhance the killing ability of CAR-NK-92 cells against the RCC cells in vitro. Furthermore, the CAR-NK-92 cells show synergistic therapeutic efficacy with cabozantinib against human RCC xenograft models. Our results provided the basis for combination with chemotherapy as a novel strategy for enhancing the therapeutic efficacy of CAR-modified immune effector cells for solid tumors.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2015JL027, BK20161157, BK2012146, BE2016643, 81301946)
- Natural Science Foundation of Jiangsu Province (ZR2015JL027, BK20161157, BK2012146, BE2016643, 81301946)
- Natural Science Foundation of Jiangsu Province (ZR2015JL027, BK20161157, BK2012146, BE2016643, 81301946)
- Jiangsu Province Social Development Key Projects (ZR2015JL027, BK20161157, BK2012146, BE2016643, 81301946)
- National Natural Science Foundation of China (ZR2015JL027, BK20161157, BK2012146, BE2016643, 81301946)
This publication has 59 references indexed in Scilit:
- Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for CancerCurrent Gene Therapy, 2013
- Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastomaBlood, 2011
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerJournal of Clinical Oncology, 2011
- Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinomaEuropean Journal of Cancer, 2011
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cellsLeukemia Research, 2009
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma PatientsClinical Cancer Research, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical ExperienceJournal of Clinical Oncology, 2006
- Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune ActivityClinical Cancer Research, 2005
- A Pilot Phase II Trial of Continuous-Infusion Interleukin-2 Followed by Lymphokine-Activated Killer Cell Therapy and Bolus-Infusion Interleukin-2 in Renal CancerJournal of Immunotherapy, 1993